Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma
- 8 July 2021
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 24 (10), 1454-1462
- https://doi.org/10.1016/j.jval.2021.04.1286
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United StatesAlimentary Pharmacology & Therapeutics, 2013
- Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage CirrhosisGastroenterology, 2013
- Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer populationJournal of Hepatology, 2012
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2011
- Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosisAlimentary Pharmacology & Therapeutics, 2009
- The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected PersonsValue in Health, 2008
- Cost‐effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstancesJournal of Gastroenterology and Hepatology, 2007
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004